AVEO +48%/PM on updated Tivozani-vs-Nexavar data in RCC: https://www.businesswire.com/news/home/20190910005358/en This is essentially a snapback to the severe selloff in early 2019 (#msg-146491381) on the hope that the Tivozanib NDA can be resuscitated.